Brief: AIM Vaccine Says Clinical Trial Application For Group's Human Rabies MRNA Vaccine Accepted
12/06/2023 13:46
June 12 (Reuters) - AIM Vaccine Co Ltd 6660.HK :
* CLINICAL TRIAL APPLICATION FOR GROUP'S HUMAN RABIES MRNA
VACCINE
ACCEPTED BY PRC NATIONAL MEDICAL PRODUCTS ADMINISTRATION
Source text for Eikon: ID:
Further company coverage: 6660.HK
Recent news on AIM Vaccine
See all newsBrief: AIM Vaccine Co Submits Application For Human Diploid Cell Rabies Vaccine In China
Brief: AIM Vaccine Says Tibet Bohai To Subscribe 37.4 Million Shares At RMB1.07 Each
Brief: AIM Vaccine Approves Issuance Of Up To 40 Million Domestic Shares
Brief: Aim Vaccine Says Serum-Free Rabies Vaccine Passes Inspection
Brief: AIM Vaccine Updates On 20-Valent Pneumococcal Polysaccharide Conjugate Vaccine